Scientific article
Open access

NAB2 is a novel immune stimulator of MDA-5 that promotes a strong type I interferon response

Published inOncotarget, vol. 9, no. 5, p. 5641-5651
Publication date2017

Novel adjuvants are needed to increase the efficacy of vaccine formulations and immune therapies for cancer and chronic infections. In particular, adjuvants that promote a strong type I IFN response are required, since this cytokine is crucial for the development of efficient anti-tumoral and anti-viral immunity. Nucleic acid band 2 (NAB2) is a double-stranded RNA molecule isolated from yeast and identified as an agonist of the pattern-recognition receptors TLR3 and MDA-5. We compared the ability of NAB2 to activate innate immunity with that of poly(I:C), a well-characterized TLR3 and MDA-5 agonist known for the induction of type I IFN. NAB2 promoted stronger IFN-α production and induced a higher activation state of both murine and human innate immune cells compared to poly(I:C). This correlated with a stronger activation of the signalling pathway downstream of MDA-5, and IFN-α induction was dependent on MDA-5. Upon injection, NAB2 induced higher levels of serum IFN-α in mice than poly(I:C). These results suggest that NAB2 has the potential to become an efficient adjuvant for the induction of type-I IFN responses in therapeutic immunization against cancer or infections.

Citation (ISO format)
OBERSON, Anne et al. NAB2 is a novel immune stimulator of MDA-5 that promotes a strong type I interferon response. In: Oncotarget, 2017, vol. 9, n° 5, p. 5641–5651. doi: 10.18632/oncotarget.23725
Main files (2)
Article (Accepted version)
Article (Published version)
ISSN of the journal1949-2553

Technical informations

Creation02/01/2019 7:12:00 PM
First validation02/01/2019 7:12:00 PM
Update time03/15/2023 3:43:57 PM
Status update03/15/2023 3:43:56 PM
Last indexation05/03/2024 7:09:11 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack